Griffin Discoveries has identified a novel dual action non imidazole H1/H4 histamine receptor antagonist that shows anti-inflammatory effects in vivo. This compound was identified among a larger series of close analogues with a favourable PK profile after oral administration. With high selectivity over the other histamine receptor subtypes, this discovery demonstrates that targeting both the H1R and H4R subtype can be achieved with a single molecule that has drug-like properties.